References [1] Kraus, D., et al
Cognitive Performance Before SS-31: mental fatigue appearing in the afternoon, difficulty sustaining focus during demanding cognitive tasks, brain fog that worsens with stress or physical fatigue
Many patients come weekly, especially while actively working toward their goals, since the shot is quick and easy to repeat
Based on the clinical evidence and the patient profiles where the compound appears most applicable, the following characteristics tend to describe good candidates for AOD 9604 evaluation when it is medically supervised: Patients with stubborn localized fat deposits that have not responded to diet and exercise, particularly visceral and lower abdominal fat Patients who cannot tolerate GLP-1 medications due to nausea, gastrointestinal side effects, or contraindications Active patients with reasonable baseline metabolic health who want a targeted lipolytic tool to complement their training and nutrition program Patients already on a peptide protocol who want to add a fat-targeting element to a GHK-Cu, NAD+, or sermorelin stack Patients who are not candidates for stimulant-based fat loss medications due to cardiovascular sensitivity, anxiety, or blood pressure concerns AOD 9604 is not appropriate as a standalone weight loss strategy for patients with significant obesity, insulin resistance, or metabolic syndrome
It is not intended for human or animal administration outside of a controlled research setting, and this article should not be read as guidance for personal or therapeutic use
However, a 1000 microgram dose of this form of vitamin B12 has about 1/10th the amount of cyanide that is recommended as the maximum water level by health Canada (200 micrograms cyanide per litre)
